View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
April 14, 2020

Coronavirus company news summary

By Allie Nawrat

The Chinese Government has approved early-stage human clinical trials of two vaccine candidates against Covid-19, according to state news agency Xinhua. The candidates are being developed by a Beijing subsidiary of Sinovac Biotech and by the Wuhan Institute of Biological Products.

RedHill Biopharma has reported preliminary data from a compassionate use programme of opaganib to treat Covid-19 patients in Israel. The results revealed that two initial patients showed clinical improvement within days after treatment-initiation with opaganib plus standard of care.

Celltrion Group has identified the most promising Covid-19 antibody therapy candidates among the initial 300 discovered in alliance with the Korea Centers for Disease Control and Prevention (KCDC). The next steps for the candidates are cell-line development and mass production, followed by efficacy and toxicity testing in mice and non-human primates.

Athersys has received the US Food and Drug Administration (FDA) approval to conduct a Phase II/III clinical trial of MultiStem therapy to treat moderate to severe acute respiratory distress syndrome caused by Covid-19. The open-label, multi-centre, randomised study will assess the therapy’s safety and efficacy.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU